O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study
Dore G, Grebely J, Altice F, Litwin A, Dalgard O, Gane E, Shibolet O, Luetkemeyer A, Nahass R, Peng C, Conway B, Iser D, Huang H, Gendrano I, Kelly M, Hwang P, Robertson M, Wahl J, Barr E, Platt H. O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study. Journal Of Virus Eradication 2017, 3: 8. DOI: 10.1016/s2055-6640(20)30904-3.Peer-Reviewed Original Research427 Hepatitis C Virus (HCV) Reinfection and Injection Risk Behavior Following Elbasvir/Grazoprevir (EBR/GZR) Treatment in Patients on Opioid Agonist Therapy (OAT): Costar Three-Year Follow-Up Study
Haber B, Gane E, Dore G, Grebely J, Altice F, Litwin A, Dalgard O, Shibolet O, Luetkemeyer A, Nahass R, Peng C, Conway B, Iser D, Huang H, Gendrano I, Kelly M, Hwang P, Robertson M, Wahl J, Barr E, Platt H. 427 Hepatitis C Virus (HCV) Reinfection and Injection Risk Behavior Following Elbasvir/Grazoprevir (EBR/GZR) Treatment in Patients on Opioid Agonist Therapy (OAT): Costar Three-Year Follow-Up Study. Gastroenterology 2017, 152: s1058-s1059. DOI: 10.1016/s0016-5085(17)33575-8.Peer-Reviewed Original Research